Gnubiotics Sciences, a Swiss biotech company pioneering the use of glycopeptides as immunomodulatory agents, recently announced an agreement with Penn to explore combining Car-T therapy with Gnubiotics’ GLAAD technology to target solid tumors.
This collaboration will take place through company-sponsored pre-clinical research studies in the laboratory of Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine.
Gnubiotics’ glycopeptides platform has been proven to drive T-cell immune responses against solid tumors in mice. Given that solid tumors typically do not respond well to Car-T therapy on its own, the hope is that combining it with glycopeptides will lead to new treatment opportunities and more extensive applications for patients.
Read the full article on the Gnubiotics website here.